| (AstraZeneca) D7630C00001 / TROPION-Breast05 | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Dr Louise Bordeleau | Open to recruitment | NCT06103864 |
| (CCTG) IND.241 - Master Protocol | A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | Dr Nidhi Kumar-Tyagi | Open to recruitment | NCT05601440 (Master) |
| (CCTG) IND.241A / Sub-Study A | Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment | Dr Nidhi Kumar-Tyagi | Suspended/On hold | NCT05601440 (A) |
| (ECRI) SIBUR | Simultaneous Integrated Boost in Ultra-Hypofractionated Adjuvant Radiotherapy for Early Stage Breast Cancer (SIBUR): A Pilot Study. | Dr Elysia Donovan | Open to recruitment | |
| (HHS) STAR-B | Stereotactic body radiotherapy (SBRT) after oligoprogression in metastatic breast cancer (STAR-B) | Dr Elysia Donovan | Open to recruitment | TBD |
| OCOG-2021-ELISA | Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features (ELISA Study) | Dr Timothy Whelan | Open to recruitment | NCT04797299 |
| OCOG-2022-RAPID2 | A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2) | Dr Do-hoon Kim | Open to recruitment | NCT05417516 |
| (CCTG) IND.241G / Sub-Study G | A PHASE II STUDY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH CDK4/6 INHIBITOR TREATED ER+/HER2- METASTATIC BREAST CANCER | Dr Nidhi Kumar-Tyagi | Suspended/On hold | NCT05601440 (G) |
Find a Trial
Contact Us